Low-dose oral hydroxychloroquine led to impaired vision in a child with renal failure Case report and literature review

被引:4
作者
Lu, Jinmiao [1 ]
Huang, Yidie [1 ]
Ye, Qiaofeng [1 ]
Shang, Feineng [2 ]
Ming, Mei [3 ]
Xu, Hong [4 ]
Li, Zhiping [1 ]
机构
[1] Fudan Univ, Dept Clin Pharm, Childrens Hosp, Shanghai 201102, Peoples R China
[2] Dehong Peoples Hosp, Dept Pharm, Dehong, Yunnan, Peoples R China
[3] Hubei Polytech Univ, Huangshi Cent Hosp, Dept Ophthalmol, Affiliated Hosp, Huangshi, Hubei, Peoples R China
[4] Fudan Univ, Dept Nephrol, Childrens Hosp, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
decreased visual acuity; hydroxychloroquine; lupus nephritis; renal hypofunction; CHLOROQUINE RETINOPATHY; RETINAL TOXICITY; RISK;
D O I
10.1097/MD.0000000000024919
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Hydroxychloroquine (HCQ) has received much attention in the treatment of coronavirus disease 2019 recently. However, it can cause irreversible vision loss. Few cases have been reported in pediatric patient with HCQ-related adverse reactions. Appropriate administration and early disease recognition are important for reducing the adverse drug reactions of HCQ. Patient concerns: We report a case of a 14-year-old Chinese girl who sought treatment for rapidly decreasing vision in the left eye over 3 days. The simulation results of the population pharmacokinetic model of HCQ revealed that the plasma concentration of HCQ abnormally increased before the visual acuity of the eye decreased. Diagnosis: She was diagnosed as HCQ related drug adverse reaction. Interventions: The daily dose of HCQ for this patient was adjusted from 100 mg/d to 50 mg/d. Outcomes: Follow-up for 6 months showed no more vision loss recurrence. However, the existing decreased visual acuity of the eye did not recover either. Conclusion: Although decreased visual acuity is an infrequent symptom, ophthalmologists should be aware of the possibility of HCQ concentration enrichment and consider minimizing HCQ use when a child with renal hypofunction seeks treatment for shortsightedness.
引用
收藏
页数:5
相关论文
共 23 条
  • [11] Drug-induced ocular disorders
    Li, Junping
    Tripathi, Ramesh C.
    Tripathi, Brenda J.
    [J]. DRUG SAFETY, 2008, 31 (02) : 127 - 141
  • [12] Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision)
    Marmor, Michael F.
    Kellner, Ulrich
    Lai, Timothy Y. Y.
    Melles, Ronald B.
    Mieler, William F.
    [J]. OPHTHALMOLOGY, 2016, 123 (06) : 1386 - 1394
  • [13] Retinal toxicity in long term hydroxychloroquine treatment
    Mavrikakis, M
    Papazoglou, S
    Sfikakis, PP
    Vaiopoulos, G
    Rougas, K
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 1996, 55 (03) : 187 - 189
  • [14] Melles RB, 2014, JAMA OPHTHALMOL, V132, P1453, DOI 10.1001/jamaophthalmol.2014.3459
  • [15] Corneal thickness and endothelial changes in long-term hydroxychloroquine use
    Ogurel, Tevfik
    Ozer, Murat Atabey
    Akbulut, Yaprak
    Gokcinar, Nesrin Buyuktortop
    Onaran, Zafer
    Ureten, Kemal
    [J]. CUTANEOUS AND OCULAR TOXICOLOGY, 2019, 38 (03) : 286 - 289
  • [16] ROSENTHAL AR, 1978, INVEST OPHTH VIS SCI, V17, P1158
  • [17] Bull's-Eye Maculopathy Associated with Hydroxychloroquine
    Sacks, Chana A.
    Modi, Yasha S.
    Singh, Rishi P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (17) : 1656 - 1656
  • [18] Savage Daniel E, 2020, Am J Ophthalmol Case Rep, V18, P100713, DOI 10.1016/j.ajoc.2020.100713
  • [19] A Case of Severe Hydroxychloroquine-Induced Retinal Toxicity in a Patient with Recent Onset of Renal Impairment: A Review of the Literature on the Use of Hydroxychloroquine in Renal Impairment
    Tailor, Rajen
    Elaraoud, Ibrahim
    Good, Peter
    Hope-Ross, Monique
    Scott, Robert A. H.
    [J]. CASE REPORTS IN OPHTHALMOLOGICAL MEDICINE, 2012, 2012
  • [20] Systemic lupus erythematosus: an expert insight into emerging therapy agents in preclinical and early clinical development
    Tocut, Milena
    Schoenfeld, Yehuda
    Zandman-Goddard, Gisele
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (10) : 1151 - 1162